Budget Impact of Andexanet ALFA for Gastrointestinal Bleeding Associated with Factor Xa Inhibitors from a US Hospital Perspective
Author(s)
Deitelzweig S1, Cash BD2, Goldstein JN3, Blissett RS4, Lovelace B5, Christoph MJ5, Fermann G6
1University of Queensland and Ochsner Clinical School, New Orleans, LA, USA, 2University of Texas Health Science Center at Houston, Houston, TX, USA, 3Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA, 4Maple Health Group, LLC, New York, NY, USA, 5Alexion, AstraZeneca Rare Disease, Boston, MA, USA, 6University of Cincinnati, Cincinnati, OH, USA
METHODS:
A decision tree framework over a 2-year time horizon was used to compare andexanet to 4-factor prothrombin complex concentrate (4F-PCC). Hospitalization costs were determined through: (1) the probability of undergoing any initial endoscopy (therapeutic or diagnostic) and (2) the risk of a re-bleeding event within 30 days. Re-bleeding events could then be treated with repeat endoscopy, angiographic embolization, or surgery. Hospitalization costs were assigned based on the level of intervention received. New technology add-on payments (NTAP) were included as an offset against pharmacy acquisition costs for andexanet. Two scenarios were modeled, a world where all patients were treated with 4F-PCC and a world where all patients were treated with andexanet (where patients in both arms could receive additional therapies including FFP, activated 4F-PCC, Vitamin K, and rFactor VIIa). The model assumed that 50 patients received reversal treatment annually with the population growing at a rate of 5% per year.RESULTS:
The budget impact was a net cost reduction of $92,626 ($1,852 per patient) in year 1 and $97,257 in year 2 when comparing a world with andexanet to a world without andexanet, driven by fewer rebleeding events and subsequent procedures. One-way sensitivity analysis showed that the most influential model parameters were the drug costs, dosing assumptions, and risk of re-bleeds. CONCLUSION: Our analysis suggests that appropriate utilization of andexanet for reversal of FXa inhibitors in the setting of major gastrointestinal bleeding may result in net reductions in hospitalization costs from a US acute care hospital perspective.Conference/Value in Health Info
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
EE391
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas